Show simple item record

dc.contributor.authorRodriguez-Martinez, Carlos E.
dc.contributor.authorSossa-Briceño, Monica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2020-02-14T18:48:38Z
dc.date.available2020-02-14T18:48:38Z
dc.identifier.issn1099-0496spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/1939
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherWileyspa
dc.relation.ispartofseriesPediatric Pulmonology, 1099-0496, 2020.spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.24650spa
dc.titleMetered‐dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost‐effectiveness analysis in a middle‐income countryspa
dc.typearticlespa
dc.type.localartículospa
dc.subject.decsInhaladores de dosis medidaspa
dc.subject.decsAnálisis costo-beneficiospa
dc.subject.decsNebulizadores y vaporizadoresspa
dc.identifier.doihttps://doi.org/10.1002/ppul.24650spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalPediatric Pulmonologyspa
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame: Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.cospa
dc.description.abstractenglishObjectives Although the benefits of albuterol delivered via metered‐dose inhalers with a spacer (MDI+S) have been increasingly recognized, the evidence regarding the cost‐effectiveness of MDI+S compared to nebulization (NEB) is not sufficient, especially in less‐affluent countries, where the clinical and economic burden of the disease is the greatest. The aim of the present study was to evaluate the cost‐effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. Methods A decision‐analysis model was developed to estimate the cost‐effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national healthcare system in Colombia, a middle‐income country (MIC). The main outcome of the model was the avoidance of hospital admission. Results For the base‐case analysis, the model showed that compared to NEB, using MDI+S for the delivery of albuterol was associated with lower total costs (US$96.68 vs US$121.41 average cost per patient) and a higher probability of hospital admission avoided (0.9219 vs 0.8900), thus leading to dominance. Conclusions This study shows that in Colombia, an MIC, compared with NEB, the use of MDI+S for delivering albuterol for the treatment of pediatric asthma exacerbations is the preferred strategy because it is associated with a lower probability of hospital admission at lower total treatment costs.spa
dc.rights.localAcceso cerradospa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf295spa
dc.date.issued2020


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record